focus -WSS

focus

author：fashion 2025-10-01 08:21:20 - browse：55

A person picking up medication at a drive through pharmacy window – biotech and pharma coverage from STAT — Adobe

On Tuesday morning, the Department of Health and Human Services unveiled its long-awaited list of the 10 medicines that will be subject to price negotiation in 2026 under the Inflation Reduction Act.

This will mark the first time that Medicare, the government program for paying for health care for older Americans, will have any ability to use its vast size to negotiate for lower prices. It’s not yet clear how big the discounts on these 10 drugs will be, or even if the law will hold up to multiple legal challenges from the pharmaceutical industry. It’s also not clear, as critics from the drug industry have noted, whether any savings to the government will be passed on to consumers.

Still, the naming of 10 medicines is a milestone, and a point to start appraising the impact of the law. The landscape here is complicated. No one really knows how the IRA’s price negotiation process will play out over the short and long term, and many companies who had products named were spared in other ways, with products many industry watchers expected to see on the list absent. Here is STAT’s assessment of who has won and lost.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： PEPFAR is under serious threat — and so is global health

WSS

PEPFAR is under serious threat — and so is global health

Telehealth for opioid use disorder is lifesaving

White House touts steps to stem shortages of cancer treatments

Can food be medicine? And other questions about a new push

Connecting traumatic brain injury and domestic violence

Inside the fall of star MIT scientist David Sabatini

explore

focus

hotspot

The high cost of giving birth even with insurance

New Covid vaccine is recommended for everyone 6 months or older

After affirmative action ruling, medical educators look to 'holistic review'

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

How one medical school became remarkably diverse

Meta looks to target Twitter with a rival app called Threads

DIEP, the 'gold standard' of breast reconstruction, is under threat

Food makers tried to stack nutrition panel with preferred experts

In age of alternative facts, a scholarly course on calling out crap

What to make of Biden’s latest efforts on cancer research

focus

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Popular nasal decongestant doesn't actually relieve congestion

Listen: PBM conflicts, RSV vaccines, & the future of flu season

Pig kidney works a record two months in donated body

Australia's humpback populations rebound raising hopes of marine scientists

Meta looks to target Twitter with a rival app called Threads

leisure time

explore

focus

focus